To evaluate the effect of Imeglimin vs metformin on blood glucose and HbA1c in newly diagnosed type 2 diabetes mellitus patients - A randomized controlled trial

Start Date07 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Imeglimin Hydrochloride

100 Translational Medicine associated with Imeglimin Hydrochloride

100 Patents (Medical) associated with Imeglimin Hydrochloride

153

Literatures (Medical) associated with Imeglimin Hydrochloride

13 Apr 2025·Expert Opinion on Pharmacotherapy

Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes

Article

Author: Tsugami, Emiko ; Inoue, Hideyuki ; Yamasaki, Tomoko ; I, Chiaki ; Togane, Michiko ; Ito, Hiroyuki ; Miura, Shun ; Antoku, Shinichi ; Matsumoto, Suzuko ; Mori, Toshiko

BACKGROUNDWe retrospectively examined the benefits and disadvantages of adding imeglimin to metformin therapy in patients with type 2 diabetes.RESEARCH DESIGN AND METHODSNinety-four patients with type 2 diabetes who had been administered imeglimin were included in the safety analysis set (SAS). Sixty-four patients who had been treated with imeglimin for over 6 months were included in the full analysis set (FAS). The primary outcome was the change in HbA1c levels in the FAS. The secondary outcomes were gastrointestinal adverse events (AEs) in the SAS and changes in body weight and FIB-4 in theFAS.RESULTSIn the SAS, gastrointestinal AEs occurred in 15 of 40 (38%) metformin users and 6 of 54 (11%) non-users. In the FAS, HbA1c levels were significantly reduced in both metformin users (n = 27, baseline, 8.5 ± 1.1%;6 months, 7.7 ± 1.2%) and non-users (n = 37, baseline, 8.0 ± 0.9%; 6 months,7.4 ± 0.9%). While body weight (from 72.0 ± 20.5 kg to 70.9 ± 20.8 kg) and FIB-4 (from 1.27 ± 0.57 to 1.17 ± 0.49) significantly decreased in metformin users, they did not significantly differ in non-users.CONCLUSIONSAdding imeglimin to metformin therapy demonstrated favorable reductions in HbA1c, body weight, and FIB-4 in patients with type 2 diabetes, although it was associated with the incidence of gastrointestinal AEs.TRIAL REGISTRATIONUMIN000055241.

01 Apr 2025·Journal of Diabetes Investigation

Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post‐hoc analysis of imeglimin clinical trial data

Article

Author: Ueki, Kohjiro ; Hagi, Katsuhiko ; Kaku, Kohei ; Kochi, Kenji ; Watada, Hirotaka ; Ito, Jumpei

ABSTRACTIntroductionAn increased rate of gastrointestinal (GI) symptoms is reported in patients with type 2 diabetes receiving imeglimin plus metformin vs monotherapy or in combination with other antidiabetic drugs. This post‐hoc analysis explored GI symptom incidence, risk factors for their occurrence, and the impact on therapeutic efficacy during imeglimin and metformin combination therapy.Materials and MethodsData were derived from the 52‐week, open‐label, phase 3 TIMES‐2 trial in Japanese type 2 diabetes patients. Patients in the imeglimin plus metformin group were divided into two subgroups based on the presence of GI symptoms and diarrhea, with efficacy and safety assessed. Factors associated with their occurrence were explored using multivariate logistic regression analysis.ResultsOf 64 patients analyzed, GI symptoms and diarrhea occurred in 40.6% (n = 26) and 17.2% (n = 11) of patients, respectively. Metformin dose and patient age did not significantly affect their incidence. Events occurred more frequently within the first 4 months of treatment. Approximately half resolved within 1 week, and most were mild. Type 2 diabetes duration <5 years was significantly associated with diarrhea (odds ratio = 5.979; P = 0.039). Significant hypoglycemic effects were observed from baseline, irrespective of GI symptoms or diarrhea. However, the degree of HbA1c improvement tended to be greater in patients with GI symptoms and diarrhea.ConclusionsIncreased awareness regarding the potential for GI symptoms, including diarrhea, during imeglimin plus metformin combination therapy is warranted. This data will provide clinicians with useful information regarding symptomatic treatment when it occurs and help determine whether to continue treatment administration and is expected to improve patient adherence.

01 Apr 2025·Diabetes Therapy

A Multicenter, Retrospective Study to Evaluate the Effectiveness and Safety of Imeglimin in Patients with Type 2 Diabetes Mellitus in a Real-World Clinical Setting (INDI-TIMES Study)

Article

Author: Shaikh, Shehla ; Sharma, Surendra K ; Baxi, Niddhi ; Bhattacharyya, Supratik ; Asirvatham, Arthur ; Muchhala, Sameer ; Dhandhania, Vinay K ; Phatak, Sanjeev

INTRODUCTIONImeglimin is a novel oral antidiabetic drug that was approved for use in India in October 2022. Thus far, no large-scale studies on the effectiveness and safety of imeglimin for the treatment of type-2 diabetes mellitus (T2DM) have been conducted in the Indian population. The objective of this study was to evaluate the effectiveness and safety of imeglimin in Indian patients with T2DM in a real-world setting.METHODSThis observational, retrospective, real-world study was conducted at 191 sites across India from May to June 2024. Adult patients with uncontrolled T2DM (7% ≤ glycated hemoglobin (HbA1c) ≤ 9%) who were prescribed imeglimin 1000 mg twice a day as part of routine clinical practice, who were either treatment naïve or on other antidiabetic agents, and for whom a valid prescription and required data were available were included in the study. The data were collected from the medical records of eligible subjects and analyzed for the changes in glycemic indices from baseline to the 3-month follow-up.RESULTThe data for 8301 patients (male: 59.39%) were analyzed. Of these, 2009 (24.20%) subjects received imeglimin monotherapy and 5004 (60.28%) received dual therapy. The analysis showed a statistically significant (p < 0.0001) reduction from baseline to the 3-month follow-up in glycemic indices and weight. The mean HbA1c, fasting and postprandial plasma glucose, and weight were decreased by 1.12%, 29.41 mg/dL, 62.41 mg/dL, and 2.01 kg, respectively. A total of 3547 (45.35%) subjects achieved HbA1c < 7%. No adverse events were reported.CONCLUSIONImeglimin shows promise as an effective and well-tolerated option for managing T2DM in the Indian population. Also, secondary impacts of imeglimin, such as improvements in the lipid profile, hepatic function, blood pressure, and weight loss, warrant further clinical exploration.

News (Medical) associated with Imeglimin Hydrochloride

31 Jan 2025

·www.businesswire.com

Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast

LYON, France--( BUSINESS WIRE )--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reports TWYMEEG ® gross sales in Japan for Q4 2024 and sales forecast shared by its partner Sumitomo Pharma as part of its Q3 FY2024 financial results 1 . “ We believe TWYMEEG ® is an important asset in our existing diabetes franchise and are committed to support its sales trajectory. Based on the safety and tolerability profile observed from TWINKLE study, we are conducting discussions with the regulatory authorities in Japan, on revising TWYMEEG ® package insert for patients with renal impairment, ” stated Koichi Kozuki, Executive Officer, Corporate Regulatory Compliance & Quality Assurance Division, Senior Vice President, Head of Corporate Regulatory Compliance & Quality Assurance Division of Sumitomo Pharma . For the quarter ending December 2024, TWYMEEG ® gross sales in Japan increased by 17% to JPY 2.1 billion (EUR 13 million) 3 over the prior quarter sales of JPY 1.8 billion (EUR 11.2 million)3 as reported by Sumitomo Pharma. As announced on January 20, 2025, TWYMEEG ® achieved JPY 5 billion net sales in Japan in Sumitomo Pharma’s fiscal year 2024 1 , making Poxel eligible for royalties equaling 10% of all TWYMEEG ® net sales for 2024 and a one-time sales-based payment of JPY 500 million (EUR 3.1 million 3 ). Based on the royalty monetization agreement with OrbiMed, these proceeds for FY2024, net of Poxel's obligation to Merck Serono, will be directed to the reimbursement of the bond issue. During FY 2024 1 , Sumitomo Pharma now expects TWYMEEG ® net sales in Japan to reach JPY 7.9 billion (EUR 48.4 million 3 ), compared to the previous forecast of JPY 11.3 billion (EUR 69.2 million 3 ) published on May 14, 2024, which would represent an increase by 72% over FY 2023 sales (JPY 4.6 billion). This revision is driven by Sumitomo Pharma’s internal restructuring initiative as well as an evolving competitive landscape in Japan. To support TWYMEEG ® sales trajectory going forward, Sumitomo Pharma has implemented measures to minimize potential impact from this internal restructuring initiative and continues to work on expanding the TWYMEEG ® package insert. As announced on August 7, 2024, topline results obtained from the post-marketing clinical study, TWINKLE ( TW YMEEG ® in d i abetic patients with re n al impairment: A post-mar k eting l ong-t e rm study) conducted by Sumitomo Pharma in Japanese type 2 diabetic patients with renal impairment confirmed TWYMEEG ® ’s safety and tolerability profile, which is consistent with prior clinical studies in the general type 2 diabetes population. Based on these results, Sumitomo Pharma is conducting discussions with the regulatory authorities in Japan for revising TWYMEEG ® package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m 2 and expects outcome in the first half of 2025. Next Financial Press Release: Fourth Quarter 2024 Cash and Revenue update, on February 19, 2025 About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology , including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770 , a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release. Glossary You will find below a list of words and/or expressions that are used in this press release or in Poxel’s communication, with the aim of bringing clarification and transparency: Sumitomo Pharma fiscal year runs April to March. As an example, Fiscal Year 2024 is April 1, 2024, through March 31, 2025. TWYMEEG royalties: As per the Sumitomo Pharma’s agreement, Poxel is entitled to receive royalties from the sales of TWYMEEG (Imeglimin) in Japan Sumitomo Pharma communicates gross sales of TWYMEEG, while TWYMEEG royalties are calculated on net sales. Net sales represent the amount of gross sales to which are deducted potential rebates, allowances, and costs such as prepaid freight, postage, shipping, customs duties and insurance charges. Poxel is entitled to receive escalating royalties of 8-18% on TWYMEEG net sales from Sumitomo Pharma. Positive net royalties : as part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of TWYMEEG, independent of the level of sales. All royalties that Poxel receives from TWYMEEG net sales above that 8% level are considered as positive net royalties. Net royalties will therefore be positive for Poxel when TWYMEEG net sales exceed JPY 5 billion in a fiscal year and royalties reach 10% and above. 1 Sumitomo Pharma fiscal year 2024 ends March 31, 2025 2 As per Sumitomo Pharma FY2024 forecast published on January 31, 2025 3 Converted at the exchange rate as of December 31, 2025. 4 As per Sumitomo Pharma FY2024 forecast published on May 14, 2024

Clinical ResultLicense out/inFinancial StatementPhase 2

20 Jan 2025

·www.businesswire.com

Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment

LYON, France--( BUSINESS WIRE )--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced that China's National Intellectual Property Administration (“CNIPA”) has granted Poxel patent ZL201980015603.X for Imeglimin, a first-in-class drug targeting mitochondrial dysfunction and marketed in Japan for the treatment of type-2 diabetes. This new patent protects the use of Imeglimin for type-2 diabetic patients with moderate to severe renal impairment until 2039. The granting of the patent further supports ongoing discussions initiated by Poxel to develop and market Imeglimin in China, following the Company's recovery of the rights to this product in Asian countries other than Japan 1 from Sumitomo Pharma. The Company also holds 3 additional patents in China covering Imeglimin’s synthesis process. The prevalence of diabetic patient with chronic kidney disease is high in China, corresponding to around 27% of the country's diabetic population, or nearly 32 million patients 2 . Diabetes is also the leading cause of end-stage renal failure in this country, i.e. requiring dialysis or a kidney transplant. China is one of Poxel's priority targets for the development and marketing of Imeglimin, where the decisions taken by the Japanese Agency for Pharmaceuticals and Medical Devices, could potentially reduce future regulatory and development times. “ The granting of this patent by the Chinese authorities is in line with our corporate development strategy and represents a partnering opportunity for a biotech company in this strategic territory. Indeed, the medical needs of the Chinese sub-population of type-2 diabetic patients with renal impairment are huge, and this sub-population is in great demand for a safe and efficacious therapeutic solution. We are pursuing our discussions with a view to a strategic partnership for the development and commercialization of Imeglimin, focusing primarily on China, South East Asian countries, as well as other very specific territories enabling us to maximize the approval of Imeglimin already achieved in Japan, thereby reducing the development efforts to be undertaken on a country-by-country basis ”, stated Thomas Kuhn, Chief Executive Officer of Poxel . About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology , including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770 , a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release. 1 China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, The Philippines, Singapore, Republic of the Union of Myanmar, Kingdom of Cambodia and Lao People's Democratic Republic. 2 Source: Chen et al. (2009) Nephrol Dial Transplant, Atkins et al. (2005) Kidney International, Robbins (2005) BMC public health

Phase 2Drug ApprovalClinical Result

20 Jan 2025

·www.businesswire.com

Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan

LYON, France--( BUSINESS WIRE )--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced that net sales of TWYMEEG ® in Japan reached JPY 5 billion (EUR 30.6 million 2 ) in Sumitomo Pharma's fiscal year 2024, making Poxel eligible for positive net royalties on net sales of the product and a sales-based payment of JPY 500 million. TWYMEEG ® is Poxel’s first-in-class product marketed for the treatment of type 2 diabetes in Japan. “ We are particularly proud that our product has reached this contractual sales threshold in Japan, paving the way for Poxel to receive positive royalties net of royalties payments to Merck Serono and a sales-based payment from our partner Sumitomo Pharma. Based on the agreement signed between Poxel and OrbiMed in September 2024, these funds will be used to repay the bonds issued to OrbiMed. Given the strong commercial momentum and Sumitomo Pharma's ongoing discussions with the Japanese authorities to revise TWYMEEG ® 's package insert for Type-2 Diabetic patients with renal impairment, we are confident of receiving escalating positive net royalties beyond 2024 ”, stated Thomas Kuhn, Chief Executive Officer of Poxel . Poxel has been informed by its partner Sumitomo Pharma that net sales of TWYMEEG ® in Japan exceeded the contractual threshold of JPY 5 billion (EUR 30.6 million 2 ) as of December 31, 2024, making Poxel eligible for royalties equaling 10% of all TWYMEEG ® net sales achieved in Japan during Sumitomo Pharma's 2024 fiscal year, and a sales-based payment of JPY 500 million (EUR 3.1 million 2 ). In accordance with the royalty monetization agreement signed with OrbiMed in September 2024, all these revenues for fiscal year 2024, after deduction of Poxel's obligation to Merck Serono, i.e. the payment of an 8% fixed royalty based on net sales, will be used to repay the bond issue. In addition, the residual amount of USD 5.0 million (EUR 4.8 million 2 ) from the reserve deposit account opened at the time of the agreement with OrbiMed, from which USD 1.25 million was withdrawn quarterly to repay the bonds issued until OrbiMed received sales-based payments and royalties based on TWYMEEG ® sales in Japan, will be used to repay the debt contracted with IPF Partners. As a result, Poxel expects that as of March 31, 2025, the level of IPF Partners' debt will be around EUR 9.3 million, including the residual amount of EUR 4.8 million from the reserve deposit account and capitalized interest. The Company's cash runway remains until the end of Q1 2025, following the non-adoption of the financial resolutions at the Company's last Combined General Meeting, held on November 28, 2024. Beyond 2024, Poxel expects to receive escalating double-digit royalties, as well as additional sales-based payments upon achievement of contractual based sales thresholds. About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology , including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770 , a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release. Glossary You will find below a list of words and/or expressions that are used in this press release or in Poxel’s communication, with the aim to bring clarification and transparency: Sumitomo Pharma fiscal year runs April to March. As an example, Fiscal Year 2024 is April 1, 2024, through March 31, 2025. TWYMEEG royalties: As per the Sumitomo Pharma’s agreement, Poxel is entitled to receive royalties from the sales of TWYMEEG (Imeglimin) in Japan Sumitomo Pharma communicates gross sales of TWYMEEG, while TWYMEEG royalties are calculated on net sales. Net sales represent the amount of gross sales to which are deducted potential rebates, allowances, and costs such as prepaid freight, postage, shipping, customs duties and insurance charges. Poxel is entitled to receive escalating royalties of 8-18% on TWYMEEG net sales from Sumitomo Pharma. Positive net royalties : as part of the Merck Serono licensing agreement, Poxel pays Merck Serono a fixed 8% royalty based on the net sales of TWYMEEG, independent of the level of sales. All royalties that Poxel receives from TWYMEEG net sales above that 8% level are considered as positive net royalties. Net royalties will therefore be positive for Poxel when TWYMEEG net sales exceed JPY 5 billion in a fiscal year and royalties reach 10% and above. 1 Sumitomo Pharma fiscal year 2024 ends March 31, 2025 2 Converted at the exchange rate on December 31, 2024

License out/inPhase 2Drug Approval

100 Deals associated with Imeglimin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Imeglimin Hydrochloride	A10B	DB12509

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Japan	Sumitomo Pharma Co., Ltd.	23 Jun 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Preclinical	Hungary	Poxel SA	26 Apr 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


907-P (ADA2024)	Not Applicable	Diabetes Mellitus, Type 2 HbA1c \| FPG \| C-peptide ... View more	32	Imeglimin 2000mg	(cnpomkajmn) = nkpfiwxtng xldbyurlow (lgywtwpcyn )	Positive	14 Jun 2024
ADA2024	Not Applicable	Diabetes Mellitus, Type 2	-	Imeglimin	(aimhfblsxp) = rqccatgovr ijyfzviaxi (vhxttipxbb, ±61.5, 95% CI 268.6 - 293.1) View more	-	14 Jun 2024
ADA2024	Not Applicable	Diabetes Mellitus, Type 2	-	Imeglimin	vpmxizwpjq(halgcvwspk) = uivopzpoks tnyonwycje (djodkuwsks )	-	14 Jun 2024
1888-LB (ADA2024)	Not Applicable	-	-	Imeglimin 2000mg/day	mhqdeuuaro(adlcyyxqkd) = lzmuvosolm caxapseiqt (zilybcbkqi, 0.1) View more	Positive	14 Jun 2024
				Metformin 1000mg/day	mhqdeuuaro(adlcyyxqkd) = zlfcuikwge caxapseiqt (zilybcbkqi, 0.1) View more
ADA2023	Not Applicable	Diabetes Mellitus Add-on	-	Imeglimin (Cluster 1)	rhjkphlpzv(yjqvzdwfai) = fupnbereqo nddhsidmxt (borkhtmxue )	-	20 Jun 2023
				Imeglimin (Cluster 2)	rhjkphlpzv(yjqvzdwfai) = jbwyctwnir nddhsidmxt (borkhtmxue )
EUCTR2013-001539-35-HU (Pubmed) Manual	Phase 2	Diabetes Mellitus, Type 2 Second line	59	imeglimin	wfnriimmgi(gloqqicvof) = euvrvtjetn lfilbdsekd (nhdgxsdcnu ) View more	Positive	14 Oct 2022
				Placebo	wfnriimmgi(gloqqicvof) = kagnaomlex lfilbdsekd (nhdgxsdcnu ) View more
JPRN-JapicCTI-173769 (TIMES 1, Pubmed \| Diabetes Care) Manual	Phase 3	Diabetes Mellitus, Type 2	213	Imeglimin	(saydnluqcf) = fjsvnobwrk ctrnhmpqyc (iqqeaubrds ) View more	Positive	01 Apr 2021
				Placebo	(iwljszsaki) = cyueacueyq yqdygpwlws (kqmkxloltc )
ESC2017	Not Applicable	Diabetic Cardiomyopathies	-	Imeglimin	vwzmxsapmz(ozjehdqhxc) = xwismneana ojddnsocyd (repkmakimj )	-	26 Aug 2017
PS 063 (EASD2016)	Not Applicable	Diabetes Mellitus, Type 2	-	Imeglimin 150mg/kg	frjteubciq(irswcohajx) = 1.4 fold increase in maximal effect cqdupjuhuc (yaxkeygzqg )	Positive	14 Sep 2016
				Imeglimin 300mg/kg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Imeglimin Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation